171 related articles for article (PubMed ID: 36362153)
1. Optimized Transcriptional Signature for Evaluation of MEK/ERK Pathway Baseline Activity and Long-Term Modulations in Ovarian Cancer.
Chesnokov MS; Yadav A; Chefetz I
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362153
[TBL] [Abstract][Full Text] [Related]
2. miRNA-651-3p regulates EMT in ovarian cancer cells by targeting ZNF703 and via the MEK/ERK pathway.
Wang S; Wang C; Liu O; Hu Y; Li X; Lin B
Biochem Biophys Res Commun; 2022 Sep; 619():76-83. PubMed ID: 35749939
[TBL] [Abstract][Full Text] [Related]
3. [Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer].
Jiang XL; Gao JC; Jiang L; Zhang PX; Kang TJ; Sun Q; Qi WJ; Zhang QP; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2019 Aug; 54(8):541-547. PubMed ID: 31461811
[No Abstract] [Full Text] [Related]
4. The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
Hendrikse CSE; Theelen PMM; van der Ploeg P; Westgeest HM; Boere IA; Thijs AMJ; Ottevanger PB; van de Stolpe A; Lambrechts S; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2023 Apr; 171():83-94. PubMed ID: 36841040
[TBL] [Abstract][Full Text] [Related]
5. Betacellulin enhances ovarian cancer cell migration by up-regulating Connexin43 via MEK-ERK signaling.
Zhao J; Klausen C; Yi Y; Cheng JC; Chang HM; Leung PCK
Cell Signal; 2020 Jan; 65():109439. PubMed ID: 31654720
[TBL] [Abstract][Full Text] [Related]
6. Propofol suppresses cell viability, cell cycle progression and motility and induces cell apoptosis of ovarian cancer cells through suppressing MEK/ERK signaling via targeting circVPS13C/miR-145 axis.
Lu H; Zheng G; Gao X; Chen C; Zhou M; Zhang L
J Ovarian Res; 2021 Feb; 14(1):30. PubMed ID: 33563314
[TBL] [Abstract][Full Text] [Related]
7. CC Chemokine 2 Promotes Ovarian Cancer Progression through the MEK/ERK/MAP3K19 Signaling Pathway.
Liu W; Wang L; Zhang J; Cheng K; Zheng W; Ma Z
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445830
[TBL] [Abstract][Full Text] [Related]
8. ERK activation and nuclear signaling induced by the loss of cell/matrix adhesion stimulates anchorage-independent growth of ovarian cancer cells.
Al-Ayoubi A; Tarcsafalvi A; Zheng H; Sakati W; Eblen ST
J Cell Biochem; 2008 Oct; 105(3):875-84. PubMed ID: 18726893
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
10. SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis.
Zhu Y; Yang L; Wang J; Li Y; Chen Y
J Gynecol Oncol; 2022 Nov; 33(6):e75. PubMed ID: 36245227
[TBL] [Abstract][Full Text] [Related]
11. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
12. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma].
Wang Y; Yang J; Gao Y; Zhao XL; Li HZ; Yao Z
Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):522-8. PubMed ID: 19957553
[TBL] [Abstract][Full Text] [Related]
14. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
15. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
Miranda MB; McGuire TF; Johnson DE
Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
[TBL] [Abstract][Full Text] [Related]
16. An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response.
Pinciroli P; Alberti C; Sensi M; Canevari S; Tomassetti A
BMC Genomics; 2013 Jul; 14():508. PubMed ID: 23889749
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
18. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
[TBL] [Abstract][Full Text] [Related]
19. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition.
Cagnol S; Rivard N
Oncogene; 2013 Jan; 32(5):564-76. PubMed ID: 22430215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
